Hematologic Oncology

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses an ongoing study examining the use of lenalidomide combined with rituximab in patients with recurrent follicular lymphoma.

OncLive spoke with Jeffrey Jones, MD, MPH, to better understand the Study 119 results, as well as the role idelalisib and other novel targeted agents will play in CLL going forward.

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses ibrutinib (Imbruvica) combined with rituximab and bendamustine (BR) as treatment of chronic lymphocytic leukemia (CLL) from a mechanism of action point of view.

Infusions of CTL019 achieved durable responses and showed an acceptable safety profile in heavily pretreated patients with CD19-positive non-Hodgkin lymphoma.

Lenalidomide in combination with rituximab and as maintenance monotherapy is highly active in patients with relapsed/refractory central nervous system non-Hodgkin lymphoma.

A chemotherapy-free combination of the anti-CD20 antibody ublituximab, ibrutinib, and the PI3K delta inhibitor TGR-1202 demonstrated robust clinical activity in patients with relapsed/refractory chronic lymphocytic leukemia or B-cell non-Hodgkin lymphoma.

The PI3Kδ inhibitor INCB040093 alone or in combination with the JAK1 inhibitor INCB039110 showed early promise in relapsed/refractory classical Hodgkin lymphoma.

Nivolumab continued to show high activity and a good safety profile after more than a year of follow-up in heavily pretreated patients with relapsed or refractory lymphoid malignancies or those with classical Hodgkin lymphoma.

The MATRIX regimen, comprised of a methotrexate/cytarabine backbone plus thiotepa and rituximab, improved outcomes in patients with primary CNS lymphoma.

TAK-659, an inhibitor of spleen tyrosine kinase, showed early signs of antitumor activity in patients with lymphoma, with two expansion arms planned for patients with diffuse large B-cell lymphoma and chronic lymphocytic leukemia.

Interim PET-CT scanning was successfully used to adapt treatment regimens in patients with advanced classical Hodgkin lymphoma.

The IDH1 inhibitor AG-120 and the IDH2 inhibitor AG-221 have demonstrated promising outcomes in patients with hematologic malignancies, including those with acute myeloid leukemia in two separate phase I clinical trials.

Treatment with inotuzumab ozogamicin demonstrated a complete response (CR) or CR with incomplete platelet recovery rate of 80.7% in patients with relapsed or refractory acute lymphoblastic leukemia.

Joseph Jurcic, MD, professor of Clinical Medicine, director of the Hematologic Malignancies Section of the Hematology/Oncology Division, Columbia University Medical Center, discusses a phase I trial of lintuzumab and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).

Over the past 30 years, survivors of childhood cancers have become less likely to die of illnesses caused by their treatment, such as new malignancies or cardiac or lung disease.

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses a recent study that examined ibrutinib combined with bendamustine and ritxuimab (BR) in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Adding ibrutinib to standard bendamustine and rituximab (BR) reduced the risk of disease progression by 80% compared with BR plus placebo in patients with pretreated CLL or SLL.

The identification of a deletion 20q in a patient with chronic lymphocytic leukemia may not indicate they have developed a myelodysplastic syndrome as was previously assumed.

William G. Wierda, MD, PhD, medical director, Leukemia Center, The University of Texas MD Anderson Cancer Center, discusses resistance to ibrutinib in patients with chronic lymphocytic leukemia (CLL).

Patients with diffuse large B-cell lymphoma who developed detectable circulating tumor DNA during surveillance were more than 200 times more likely to have their disease progress than those who did not have detectable ctDNA.

In an interview with OncLive, John Radford, MD, discusses the impact of novel agents in non-Hodgkin lymphoma and what continued research is necessary to overcome treatment challenges.

Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses deferasirox (Exjade) in iron chelation therapy for patients with myelodysplastic syndromes (MDS).

Danielle Townsley, MD, staff clinician, Cell Biology Section, National Institutes of Health, discusses a study which examined screening for GATA2 in patients who are at risk for myelodysplastic syndromes (MDS), aplastic anemia (AA), and acute myeloid leukemia (AML).

A biomarker model that incorporates the mutational status of multiple somatic genes could be used to predict response to hypomethylating agents for patients with myelodysplastic syndromes.